These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28283481)

  • 21. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 22. Intra-heterogeneity in transcription and chemoresistant property of leukemia-initiating cells in murine Setd2
    Song J; Du L; Liu P; Wang F; Zhang B; Xie Y; Lu J; Jin Y; Zhou Y; Lv G; Zhang J; Chen S; Chen Z; Sun X; Zhang Y; Huang Q
    Cancer Commun (Lond); 2021 Sep; 41(9):867-888. PubMed ID: 34196511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
    Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
    J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
    Weidenaar AC; Ter Elst A; Kampen KR; Meeuwsen-de Boer T; Kamps WA; Schuringa JJ; de Bont ES
    Mol Cancer Res; 2013 Apr; 11(4):339-48. PubMed ID: 23393162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
    Sasca D; Szybinski J; Schüler A; Shah V; Heidelberger J; Haehnel PS; Dolnik A; Kriege O; Fehr EM; Gebhardt WH; Reid G; Scholl C; Theobald M; Bullinger L; Beli P; Kindler T
    Blood; 2019 May; 133(21):2305-2319. PubMed ID: 30814062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
    Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
    Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
    Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
    Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of cantharidins on leukemic stem cells.
    Dorn DC; Kou CA; Png KJ; Moore MA
    Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
    Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
    Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW
    Cell Stem Cell; 2014 Dec; 15(6):775-90. PubMed ID: 25479751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
    Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
    Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells.
    Cornet-Masana JM; Moreno-Martínez D; Lara-Castillo MC; Nomdedeu M; Etxabe A; Tesi N; Pratcorona M; Esteve J; Risueño RM
    Oncotarget; 2016 Apr; 7(17):23239-50. PubMed ID: 26992240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.
    Su R; Lin HS; Zhang XH; Yin XL; Ning HM; Liu B; Zhai PF; Gong JN; Shen C; Song L; Chen J; Wang F; Zhao HL; Ma YN; Yu J; Zhang JW
    Oncogene; 2015 Jun; 34(25):3226-39. PubMed ID: 25174404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.
    Saito Y; Chapple RH; Lin A; Kitano A; Nakada D
    Cell Stem Cell; 2015 Nov; 17(5):585-96. PubMed ID: 26440282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
    Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
    Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.